Objectives: Relevance of training has been recognized as a key factor for safety of Carotid stenting (CAS).
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The Influence of Gender on Functional Outcomes of Lower Extremity Bypass
Results: On univariate analysis woman had less CAD (35% vs. 40 %, P Ͻ.001), smoking (75% vs. 89%, P ϭ .002), and autogenous conduits (63% vs. 71%, P Ͻ.001). Women had higher rates of reoperation for thrombosis (4% vs. 2%; OR 2.09, P Ͻ.001) or infection (2% vs. 1%; OR 2.36, P ϭ .02) without differences in graft patency (94% vs. 95%; P ϭ .25) or mortality (2.1% vs. 2.1%; P ϭ .84) at discharge. Multivariate analysis showed fewer women were discharged home (63% vs. 73%; OR 0.72, P Ͻ.001) and ambulating at discharge (90% vs. 93%; OR 0.65, P ϭ .009) regardless of preoperative ambulation. At long-term follow-up fewer women lived independently (HR 1.46, P ϭ .06) and significantly fewer were ambulatory (HR 1.65, P ϭ .004) (Fig) .
Conclusions: Women have similar procedural-related complications but slightly inferior early and late functional outcomes after LEB. These findings may help define physician and patient expectations in women before revascularization.
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Methods: All LEB in our institutional registry for occlusive disease from 1/05-7/11 were included. 519 LEB underwent 1:1 propensity score matching to create similar PS and no-PS cohorts. The primary endpoint was a composite of hemorrhagic complications (hematoma, re-op for bleeding, transfusion). 30-day graft patency was a secondary endpoint.
Results: 358 matched bypasses were analyzed: 179 received PS and 179 did not. The propensity matched groups were similar across all assessed variables (Table) . By univariate analysis, the PS and no-PS groups had similar rates of postop hematoma (5.6% vs 3.3%, P ϭ .44), re-exploration for bleeding (1.7% vs 1.1%, P ϭ .84), transfusion (20.1% vs 18.4%, P ϭ .79), and composite "any-bleeding complication" (24.6% vs 20.7%, P ϭ .45). Each group had a similar 30-day primary patency rate of 96%. By multivariable analysis, PS use did not reduce hemorrhagic complications (OR 0.8;95% CI 0.48-1.3; P ϭ .35) and was not associated with loss of primary patency (HR 0.72;95% CI 0.49-1.05; P ϭ .1).
Conclusions: This propensity matched analysis demonstrates that while selective use of PS was not protective against hemorrhagic complications, it appears safe for use even in grafts at higher risk of thrombosis. Objectives: 30-day URA after LEB is large cost-burden and a target for cost containment strategies. We undertook this study to identify factors associated with URA after LEB.
Methods: This is a retrospective analysis from a prospective institutional registry. All LEBs for occlusive disease from 1/95-7/11 were included. The primary endpoint was 30-day URA.
Results: Of 1543 LEBs, 27 patients (1.7%) died in house and were excluded. Of 1516 remaining LEBs, 84.5% were for CLI and 349 (23.0%) had 30-day URA. Univariate predictors of URA are shown in the Table. By multivariable analysis, pre-operative factors predictive of URA were: Dialysis (OR 1.73, P ϭ .004), Tissue loss (OR 1.62, P ϭ .0004), and CHF (OR 1.43, P Ͻ.03). Postoperative predictors included: SFA inflow source (OR 1.38, P ϭ .016), wound infection (OR 8.30, P Ͻ.0001) in-hospital graft failure (OR 3.20, P Ͻ.0001) and MI (OR 1.96, P Ͻ.04). Conduit type, LOS, and discharge disposition did not predict URA. URA independently predicted loss of assisted primary patency (HR 1.39, P ϭ .01) and long-term limb loss (HR 1.68, P ϭ .001).
Conclusions: 30-day URA is frequent following LEB (23%). It is essential to consider risk factors associated with URA for quality improvement and equitable resource allocation when disease-specific bundling strategies are being derived. 
